Welcome to our dedicated page for HilleVax news (Ticker: $HLVX), a resource for investors and traders seeking the latest updates and insights on HilleVax stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect HilleVax's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of HilleVax's position in the market.
Rhea-AI Summary
HilleVax, Inc. (HLVX) reports financial results for 2023, highlights progress on HIL-214 vaccine development for norovirus-related gastroenteritis, with topline data expected in mid-2024. The company had $303.5 million in cash and securities as of December 31, 2023. Recent business highlights include new COO appointment and successful public stock offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.49%
Tags
-
Rhea-AI Summary
HilleVax, Inc. (Nasdaq: HLVX) will present at the Guggenheim 6th Annual Biotechnology Conference to discuss HIL-214, its investigational virus-like particle (VLP) based vaccine for the prevention of norovirus-related acute gastroenteritis. The company focuses on developing and commercializing novel vaccines to address the global burden of norovirus, which results in over 700 million cases of acute gastroenteritis and 200,000 deaths annually, with significant economic impact.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.58%
Tags
-
News
Rhea-AI Summary
HilleVax, Inc. (Nasdaq: HLVX) announced the appointment of Sean McLoughlin as Chief Operating Officer, with Dr. Aditya Kohli transitioning to Chief Business Officer. McLoughlin brings three decades of experience in vaccines, previously serving in leadership roles at GSK. His appointment is expected to support the progress of NEST-IN1, HilleVax's Phase 2b clinical trial of HIL-214 for norovirus prevention.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.89%
Tags
Rhea-AI Summary
HilleVax, Inc. (Nasdaq: HLVX) and Chengdu Kanghua Biological Products Co., Ltd. (Kangh) (SHE: 300841) have entered into an exclusive license agreement for rights to Kangh’s hexavalent virus-like particle (VLP) vaccine candidate for norovirus, referred to by HilleVax as HIL-216, outside of Greater China. This collaboration adds a Phase 1-ready next-generation program to HilleVax’s pipeline and includes VLPs for six of the most common norovirus genotypes. The Investigational New Drug (IND) application for HIL-216 was cleared by the U.S. FDA in September 2023. HilleVax will pay Kangh an upfront payment of $15 million with the potential for additional payments of up to $255.5 million upon achieving certain development and sales milestones. Kangh is also eligible to receive a single-digit tiered royalty on net sales outside of Greater China.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.05%
Tags
-
Rhea-AI Summary
HilleVax, Inc. (Nasdaq: HLVX) will present at the 42nd Annual J.P. Morgan Healthcare Conference to discuss HIL-214, an investigational virus-like particle (VLP) based vaccine for the prevention of norovirus-related acute gastroenteritis, and the ongoing Phase 2b study NEST-IN1. The presentation will be held on January 8, 2024, at 1:30 p.m. PST in San Francisco, California.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.66%
Tags
-
Rhea-AI Summary
HilleVax, Inc. (HLVX) Reports Strong Financial Results and Progress on HIL-214 Vaccine Development
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.18%
Tags
Rhea-AI Summary
HilleVax, Inc. will be presenting at the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference on November 6, 2023, and at the Stifel Healthcare Conference on November 14, 2023. The focus of the presentations will be on HilleVax's investigational virus-like particle (VLP) based vaccine for norovirus-related acute gastroenteritis and the ongoing Phase 2b study NEST-IN1.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.68%
Tags
-
Rhea-AI Summary
HilleVax, Inc. to present at Cantor Global Healthcare Conference on September 28, 2023. Discussion to focus on HIL-214 vaccine for norovirus prevention. Webcast available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.07%
Tags
-
Rhea-AI Summary
HilleVax closes public offering, raising $115.0 million for clinical development of HIL-214 vaccine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.31%
Tags
Rhea-AI Summary
HilleVax, Inc. announces pricing of public offering of 8,000,000 shares of common stock at $12.50 per share, expected to raise $100.0 million
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.97%
Tags
HilleVax, Inc.
Nasdaq:HLVX
HLVX Rankings
HLVX Stock Data
697.09M
23.43M
5.72%
76.49%
0.9%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
United States of America
BOSTON
About HLVX
hillevax is a biopharmaceutical company focused on the development and commercialization of novel vaccines. our initial program, hil-214, is a virus-like particle (vlp) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.